- Home
- JBI vs PCRX Comparison
JBI vs PCRX Comparison
Compare JBI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBI
- PCRX
- Stock Information
- Founded
- JBI 2002
- PCRX 2006
- Country
- JBI United States
- PCRX United States
- Employees
- JBI N/A
- PCRX N/A
- Industry
- JBI Building Products
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- JBI Industrials
- PCRX Health Care
- Exchange
- JBI Nasdaq
- PCRX Nasdaq
- Market Cap
- JBI 1.2B
- PCRX 1.2B
- IPO Year
- JBI N/A
- PCRX 2011
- Fundamental
- Price
- JBI $9.92
- PCRX $25.22
- Analyst Decision
- JBI Buy
- PCRX Buy
- Analyst Count
- JBI 4
- PCRX 5
- Target Price
- JBI $10.50
- PCRX $32.40
- AVG Volume (30 Days)
- JBI 738.1K
- PCRX 599.0K
- Earning Date
- JBI 10-28-2025
- PCRX 11-05-2025
- Dividend Yield
- JBI N/A
- PCRX N/A
- EPS Growth
- JBI N/A
- PCRX N/A
- EPS
- JBI 0.30
- PCRX N/A
- Revenue
- JBI $899,500,000.00
- PCRX $705,848,000.00
- Revenue This Year
- JBI N/A
- PCRX $7.36
- Revenue Next Year
- JBI $3.56
- PCRX $10.07
- P/E Ratio
- JBI $32.91
- PCRX N/A
- Revenue Growth
- JBI N/A
- PCRX 2.25
- 52 Week Low
- JBI $5.99
- PCRX $13.89
- 52 Week High
- JBI $10.80
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- JBI 46.21
- PCRX 40.72
- Support Level
- JBI $9.83
- PCRX $25.74
- Resistance Level
- JBI $10.09
- PCRX $26.94
- Average True Range (ATR)
- JBI 0.30
- PCRX 0.82
- MACD
- JBI -0.07
- PCRX -0.28
- Stochastic Oscillator
- JBI 11.39
- PCRX 20.47
About JBI Janus International Group Inc.
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.